{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:54:15Z","timestamp":1794369255302,"version":"4.9.0"},"publisher-location":"Totowa, NJ","reference-count":108,"publisher":"Humana Press","isbn-type":[{"value":"9781588297105","type":"print"},{"value":"9781603270298","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010]]},"DOI":"10.1007\/978-1-60327-029-8_8","type":"book-chapter","created":{"date-parts":[[2009,12,14]],"date-time":"2009-12-14T13:43:18Z","timestamp":1260798198000},"page":"123-144","source":"Crossref","is-referenced-by-count":75,"title":["Nanoparticle and Iron Chelators as a Potential Novel Alzheimer Therapy"],"prefix":"10.1007","author":[{"given":"Gang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Men","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,11,25]]},"reference":[{"key":"8_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0074-7742(08)60607-8","volume":"42","author":"M.A. Smith","year":"1998","unstructured":"Smith, M.A. (1998) Alzheimer disease. Int. Rev. Neurobiol. 42, 1\u201354.","journal-title":"Int. Rev. Neurobiol"},{"key":"8_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1749-6632.1994.tb21805.x","volume":"738","author":"J.M. Gutteridge","year":"1994","unstructured":"Gutteridge, J.M. (1994) Hydroxyl radicals, iron, oxidative stress, and neurodegeneration. Ann. NY Acad. Sci. 738, 201\u2013213.","journal-title":"Ann. NY Acad. Sci"},{"key":"8_CR3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/oxfordjournals.bmb.a072632","volume":"49","author":"P.H. Evans","year":"1993","unstructured":"Evans, P.H. (1993) Free radicals in brain metabolism and pathology. Br. Med. Bull. 49, 577\u2013587.","journal-title":"Br. Med. Bull"},{"key":"8_CR4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3233\/JAD-1998-1103","volume":"1","author":"G. Perry","year":"1998","unstructured":"Perry, G., Castellani, R.J., Hirai, K., and Smith, M.A. (1998) Reactive oxygen species mediate cellular damage in Alzheimer disease. J. Alzheimer\u2019s Dis. 1, 45\u201355.","journal-title":"J. Alzheimer\u2019s Dis"},{"key":"8_CR5","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/0166-2236(95)93897-7","volume":"18","author":"M.A. Smith","year":"1995","unstructured":"Smith, M.A., Sayre, L.M., Monnier, V.M., and Perry, G. (1995) Radical AGEing in Alzheimer\u2019s disease. Trends Neurosci. 18, 172\u2013176.","journal-title":"Trends Neurosci"},{"key":"8_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/00002826-200001000-00002","volume":"23","author":"K.N. Prasad","year":"2000","unstructured":"Prasad, K.N., Hovland, A.R., Cole, W.C., Prasad, K.C., Nahreini, P., Edwards-Prasad, J., and Andreatta, C.P. (2000) Multiple antioxidants in the prevention and treatment of Alzheimer disease: Analysis of biologic rationale. Clin. Neuropharmacol. 23, 2\u201313.","journal-title":"Clin. Neuropharmacol"},{"key":"8_CR7","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/j.1532-5415.1998.tb01544.x","volume":"46","author":"S.S. Pitchumoni","year":"1998","unstructured":"Pitchumoni, S.S. and Doraiswamy, P.M. (1998) Current status of antioxidant therapy for Alzheimer\u2019s disease. J. Am. Geriatr. Soc. 46, 1566\u20131572.","journal-title":"J. Am. Geriatr. Soc"},{"key":"8_CR8","doi-asserted-by":"crossref","first-page":"621S","DOI":"10.1093\/ajcn\/71.2.621s","volume":"71","author":"Y. Christen","year":"2000","unstructured":"Christen, Y. (2000) Oxidative stress and Alzheimer disease. Am. J. Clin. Nutr. 71, 621S\u2013629S.","journal-title":"Am. J. Clin. Nutr"},{"key":"8_CR9","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1038\/nm1196-1230","volume":"2","author":"M.L. Kennard","year":"1996","unstructured":"Kennard, M.L., Feldman, H., Yamada, T., and Jefferies, W.A. (1996) Serum levels of the iron binding protein p97 are elevated in Alzheimer\u2019s disease. Nat. Med. 2, 1230\u20131235.","journal-title":"Nat. Med"},{"key":"8_CR10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/0006-8993(95)01407-1","volume":"712","author":"W.A. Jefferies","year":"1996","unstructured":"Jefferies, W.A., Food, M.R., Gabathuler, R., Rothenberger, S., Yamada, T., Yasuhara, O., and McGeer, P.L. (1996) Reactive microglia specifically associated with amyloid plaques in Alzheimer\u2019s disease brain tissue express melanotransferrin. Brain Res. 712, 122\u2013126.","journal-title":"Brain Res"},{"key":"8_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/BF02436085","volume":"18","author":"D. Harman","year":"1995","unstructured":"Harman, D. (1995) Free radical theory of aging: Alzheimer\u2019s disease pathogensis. Age, 18, 97\u2013119.","journal-title":"Age"},{"key":"8_CR12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3233\/JAD-2004-6208","volume":"6","author":"G. Casadesus","year":"2004","unstructured":"Casadesus, G., Smith, M.A., Zhu, X., Aliev, G., Cash, A.D., Honda, K., Petersen, R.B., and Perry, G. (2004) Alzheimer disease: Evidence for a central pathogenic role of iron-mediated reactive oxygen species. J. Alzheimer\u2019s Dis. 6, 165\u2013169.","journal-title":"J. Alzheimer\u2019s Dis"},{"key":"8_CR13","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1002\/ana.410320703","volume":"32","author":"C.W. Olanow","year":"1992","unstructured":"Olanow, C.W. (1992) An introduction to the free radical hypothesis in Parkinson\u2019s disease. Ann. Neurol. 32(Suppl), S2\u2013S9.","journal-title":"Ann. Neurol"},{"key":"8_CR14","volume-title":"Free Radicals in Biology and Medicine","year":"1999","unstructured":"Halliwell, B. and Gutteridge, J.M.C. (Ed.) (1999) Free Radicals in Biology and Medicine, Oxford University, New York."},{"key":"8_CR15","first-page":"401","volume-title":"Alzheimer Disease","author":"W.R. Markesbery","year":"1999","unstructured":"Markesbery, W.R. and Ehmann, W.D. (1999) Oxidative stress in Alzheimer disease. In: Alzheimer Disease (Terry, R.D., Katzman, R., Bick, K.L., and Sisodia, S.S., Eds.), Lippincott Williams & Wilkins, Philadelphia, pp. 401\u2013414."},{"key":"8_CR16","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1248\/cpb.31.1415","volume":"31","author":"M. Ohtawa","year":"1983","unstructured":"Ohtawa, M., Seko, M., and Takayama, F. (1983) Effect of aluminum ingestion on lipid peroxidation in rats. Chem. Pharm. Bull. (Tokyo), 31, 1415\u20131418.","journal-title":"Chem. Pharm. Bull"},{"key":"8_CR17","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3109\/10715768909055157","volume":"6","author":"P.H. Evans","year":"1989","unstructured":"Evans, P.H., Klinowski, J., Yano, E., and Urano, N. (1989) Alzheimer\u2019s disease: A pathogenic role for aluminosilicate-induced phagocytic free radicals. Free Radic. Res. Commun. 6, 317\u2013321.","journal-title":"Free Radic. Res. Commun"},{"key":"8_CR18","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1749-6632.1994.tb21837.x","volume":"738","author":"C. Garrel","year":"1994","unstructured":"Garrel, C., Lafond, J.L., Guiraud, P., Faure, P., and Favier, A. (1994) Induction of production of nitric oxide in microglial cells by insoluble form of aluminium. Ann. NY Acad. Sci. 738, 455\u2013461.","journal-title":"Ann. NY Acad. Sci"},{"key":"8_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/0891-5849(92)90168-G","volume":"13","author":"S. Kong","year":"1992","unstructured":"Kong, S., Liochev, S., and Fridovich, I. (1992) Aluminum(III) facilitates the oxidation of NADH by the superoxide anion. Free Radic. Biol. Med. 13, 79\u201381.","journal-title":"Free Radic. Biol. Med"},{"key":"8_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0006-8993(98)00461-2","volume":"799","author":"S.C. Bondy","year":"1998","unstructured":"Bondy, S.C., Guo-Ross, S.X., and Truong, A.T. (1998) Promotion of transition metal-induced reactive oxygen species formation by beta-amyloid. Brain Res. 799, 91\u201396.","journal-title":"Brain Res"},{"key":"8_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0022-510X(98)00092-6","volume":"158","author":"M.A. Lovell","year":"1998","unstructured":"Lovell, M.A., Robertson, J.D., Teesdale, W.J., Campbell, J.L., and Markesbery, W.R. (1998) Copper, iron and zinc in Alzheimer\u2019s disease senile plaques. J. Neurol. Sci. 158, 47\u201352.","journal-title":"J. Neurol. Sci"},{"key":"8_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1750-3639.1999.tb00215.x","volume":"9","author":"W.R. Markesbery","year":"1999","unstructured":"Markesbery, W.R. and Carney, J.M. (1999) Oxidative alterations in Alzheimer\u2019s disease. Brain Pathol. 9, 133\u2013146.","journal-title":"Brain Pathol"},{"key":"8_CR23","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1126\/science.271.5254.1406","volume":"271","author":"G. Multhaup","year":"1996","unstructured":"Multhaup, G., Schlicksupp, A., Hesse, L., Beher, D., Ruppert, T., Masters, C.L., and Beyreuther, K. (1996) The amyloid precursor protein of Alzheimer\u2019s disease in the reduction of copper(II) to copper(I). Science, 271, 1406\u20131409.","journal-title":"Science"},{"key":"8_CR24","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S1367-5931(99)80035-0","volume":"3","author":"L.M. Sayre","year":"1999","unstructured":"Sayre, L.M., Perry, G., and Smith, M.A. (1999) Redox metals and neurodegenerative disease. Curr. Opin. Chem. Biol. 3, 220\u2013225.","journal-title":"Curr. Opin. Chem. Biol"},{"key":"8_CR25","doi-asserted-by":"crossref","first-page":"797S","DOI":"10.1093\/ajcn\/63.5.797","volume":"63","author":"M.C. Linder","year":"1996","unstructured":"Linder, M.C. and Hazegh-Azam, M. (1996) Copper biochemistry and molecular biology. Am. J. Clin. Nutr. 63, 797S\u2013811S.","journal-title":"Am. J. Clin. Nutr"},{"key":"8_CR26","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1126\/science.8073293","volume":"265","author":"A.I. Bush","year":"1994","unstructured":"Bush, A.I., Pettingell, W.H., Multhaup, G., d Paradis, M., Vonsattel, J.P., Gusella, J.F., Beyreuther, K., Masters, C.L., and Tanzi, R.E. (1994) Rapid induction of Alzheimer A beta amyloid formation by zinc. Science, 265, 1464\u20131467.","journal-title":"Science"},{"key":"8_CR27","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1073\/pnas.91.8.3270","volume":"91","author":"K. Hensley","year":"1994","unstructured":"Hensley, K., Carney, J.M., Mattson, M.P., Aksenova, M., Harris, M., Wu, J.F., Floyd, R.A., and Butterfield, D.A. (1994) A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease. Proc. Natl. Acad. Sci. USA, 91, 3270\u20133274.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"8_CR28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1021\/tx960130e","volume":"10","author":"D.A. Butterfield","year":"1997","unstructured":"Butterfield, D.A. (1997) beta-Amyloid-associated free radical oxidative stress and neurotoxicity: Implications for Alzheimer\u2019s disease. Chem. Res. Toxicol. 10, 495\u2013506.","journal-title":"Chem. Res. Toxicol"},{"key":"8_CR29","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1001\/archneur.59.6.972","volume":"59","author":"D. Pratico","year":"2002","unstructured":"Pratico, D., Clark, C.M., Liun, F., Rokach, J., Lee, V.Y., and Trojanowski, J.Q. (2002) Increase of brain oxidative stress in mild cognitive impairment: A possible predictor of Alzheimer disease. Arch. Neurol. 59, 972\u2013976.","journal-title":"Arch. Neurol"},{"key":"8_CR30","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1046\/j.1471-4159.2000.0751219.x","volume":"75","author":"C.S. Atwood","year":"2000","unstructured":"Atwood, C.S., Scarpa, R.C., Huang, X., Moir, R.D., Jones, W.D., Fairlie, D.P., Tanzi, R.E., and Bush, A.I. (2000) Characterization of copper interactions with alzheimer amyloid beta peptides: Identification of an attomolar-affinity copper binding site on amyloid beta1-42. J. Neurochem. 75, 1219\u20131233.","journal-title":"J. Neurochem"},{"key":"8_CR31","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1096\/fj.02-0012fje","volume":"16","author":"D. Pratico","year":"2002","unstructured":"Pratico, D., Uryu, K., Sung, S., Tang, S., Trojanowski, J.Q., and Lee, V.M. (2002) Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice. FASEB J. 16, 1138\u20131140.","journal-title":"FASEB J"},{"key":"8_CR32","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3233\/JAD-2004-6310","volume":"6","author":"E. House","year":"2004","unstructured":"House, E., Collingwood, J., Khan, A., Korchazkina, O., Berthon, G., and Exley, C. (2004) Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer\u2019s disease. J. Alzheimer\u2019s Dis. 6, 291\u2013301.","journal-title":"J. Alzheimer\u2019s Dis"},{"key":"8_CR33","first-page":"793","volume":"145","author":"D.R. McLachlan","year":"1991","unstructured":"McLachlan, D.R., Kruck, T.P., Lukiw, W.J., and Krishnan, S.S. (1991) Would decreased aluminum ingestion reduce the incidence of Alzheimer\u2019s disease? CMAJ, 145, 793\u2013804.","journal-title":"CMAJ"},{"key":"8_CR34","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1749-6632.2000.tb06938.x","volume":"920","author":"M.P. Cuajungco","year":"2000","unstructured":"Cuajungco, M.P., Faget, K.Y., Huang, X., Tanzi, R.E., and Bush, A.I. (2000) Metal chelation as a potential therapy for Alzheimer\u2019s disease. Ann. NY Acad. Sci. 920, 292\u2013304.","journal-title":"Ann. NY Acad. Sci"},{"key":"8_CR35","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/(SICI)1096-8652(199808)58:4<299::AID-AJH9>3.0.CO;2-L","volume":"58","author":"D.R. Richardson","year":"1998","unstructured":"Richardson, D.R. and Ponka, P. (1998) Development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism. Am. J. Hematol. 58, 299\u2013305.","journal-title":"Am. J. Hematol"},{"key":"8_CR36","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/j.1749-6632.1965.tb54077.x","volume":"119","author":"H. Keberle","year":"1964","unstructured":"Keberle, H. (1964) The biochemistry of desferrioxamine and its relation to iron metabolism. Ann. NY Acad. Sci. 119, 758\u2013768.","journal-title":"Ann. NY Acad. Sci"},{"key":"8_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0079-6468(08)70363-1","volume":"28","author":"R.C. Hider","year":"1991","unstructured":"Hider, R.C. and Hall, A.D. (1991) Clinically useful chelators of tripositive elements. Prog. Med. Chem. 28, 41\u2013173.","journal-title":"Prog. Med. Chem"},{"key":"8_CR38","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1046\/j.1532-5415.2003.51368.x","volume":"51","author":"A.E. Finefrock","year":"2003","unstructured":"Finefrock, A.E., Bush, A.I., and Doraiswamy, P.M. (2003) Current status of metals as therapeutic targets in Alzheimer\u2019s disease. J. Am. Geriatr. Soc. 51, 1143\u20131148.","journal-title":"J. Am. Geriatr. Soc"},{"key":"8_CR39","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1111\/j.1471-4159.1991.tb06358.x","volume":"57","author":"D. Ben-Shachar","year":"1991","unstructured":"Ben-Shachar, D., Riederer, P., and Youdim, M.B. (1991) Iron-melanin interaction and lipid peroxidation: Implications for Parkinson\u2019s disease. J. Neurochem. 57, 1609\u20131614.","journal-title":"J. Neurochem"},{"key":"8_CR40","first-page":"709","volume":"46","author":"E. Floor","year":"2000","unstructured":"Floor, E. (2000) Iron as a vulnerability factor in nigrostriatal degeneration in aging and Parkinson\u2019s disease. Cell Mol. Biol. (Noisy-le-grand), 46, 709\u2013720.","journal-title":"Cell Mol. Biol"},{"key":"8_CR41","first-page":"345","volume":"56","author":"D.R. Blake","year":"1985","unstructured":"Blake, D.R., Winyard, P., Lunec, J., Williams, A., Good, P.A., Crewes, S.J., Gutteridge, J.M., Rowley, D., Halliwell, B., Cornish, A. et al. (1985) Cerebral and ocular toxicity induced by desferrioxamine. Q. J. Med. 56, 345\u2013355.","journal-title":"Q. J. Med"},{"key":"8_CR42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/clpt.1993.6","volume":"53","author":"T.P. Kruck","year":"1993","unstructured":"Kruck, T.P., Fisher, E.A., and McLachlan, D.R. (1993) A predictor for side effects in patients with Alzheimer\u2019s disease treated with deferoxamine mesylate. Clin. Pharmacol. Ther. 53, 30\u201337.","journal-title":"Clin. Pharmacol. Ther"},{"key":"8_CR43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/978-3-7091-9322-8_14","volume-title":"Iron in Central Nervous System Disorders","author":"M. Struck","year":"1993","unstructured":"Struck, M., Waldmeier, P., and Berdoukas, V. (1993) The treatment of iron overload-psychiatric implication. In: Iron in Central Nervous System Disorders (Riederer, P. and Youdim, M.B.H., Eds.) Springer Verlag, Wien, pp. 189\u2013196."},{"key":"8_CR44","first-page":"1649","volume-title":"Goodman and Gilman\u2019s The Pharmacological Basis of Therapeutics","author":"C.D. Klaasen","year":"1996","unstructured":"Klaasen, C.D. (1996) Heavy metals and heavy-metalantagonists. In: Goodman and Gilman\u2019s The Pharmacological Basis of Therapeutics (Hardman, J.G., Limbird, L.E., Molinoff, P.B., Ruddon, R.W., and Gilman, A.G., Eds.), McGraw Hill, New York, pp. 1649\u20131671."},{"key":"8_CR45","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1002\/ana.410440712","volume":"44","author":"P. Jenner","year":"1998","unstructured":"Jenner, P. and Olanow, C.W. (1998) Understanding cell death in Parkinson\u2019s disease. Ann. Neurol. 44, S72\u2013S84.","journal-title":"Ann. Neurol"},{"key":"8_CR46","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0079-6468(08)70220-0","volume":"20","author":"P.M. May","year":"1983","unstructured":"May, P.M. and Bulman, R.A. (1983) The present status of chelating agents in medicine. Prog. Med. Chem. 20, 225\u2013336.","journal-title":"Prog. Med. Chem"},{"key":"8_CR47","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood.V89.3.739","volume":"89","author":"N.F. Olivieri","year":"1997","unstructured":"Olivieri, N.F. and Brittenham, G.M. (1997) Iron-chelating therapy and the treatment of thalassemia. Blood, 89, 739\u2013761.","journal-title":"Blood"},{"key":"8_CR48","first-page":"865","volume":"46","author":"S.G. Lynch","year":"2000","unstructured":"Lynch, S.G., Fonseca, T., and Levine, S.M. (2000) A multiple course trial of desferrioxamine in chronic progressive multiple sclerosis. Cell Mol. Biol. (Noisy-le-grand), 46, 865\u2013869.","journal-title":"Cell Mol. Biol"},{"key":"8_CR49","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/BF00966731","volume":"19","author":"A. Crowe","year":"1994","unstructured":"Crowe, A. and Morgan, E.H. (1994) Effects of chelators on iron uptake and release by the brain in the rat. Neurochem. Res. 19, 71\u201376.","journal-title":"Neurochem. Res"},{"key":"8_CR50","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1039\/an9952000845","volume":"120","author":"G.J. Kontoghiorghes","year":"1995","unstructured":"Kontoghiorghes, G.J. (1995) New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review. Analyst, 120, 845\u2013851.","journal-title":"Analyst"},{"key":"8_CR51","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/0006-2952(94)00521-M","volume":"49","author":"R.J. Ward","year":"1995","unstructured":"Ward, R.J., Dexter, D., Florence, A., Aouad, F., Hider, R., Jenner, P., and Crichton, R.R. (1995) Brain iron in the ferrocene-loaded rat: Its chelation and influence on dopamine metabolism. Biochem. Pharmacol. 49, 1821\u20131826.","journal-title":"Biochem. Pharmacol"},{"key":"8_CR52","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1517\/13543784.8.12.2141","volume":"8","author":"D.R. Richardson","year":"1999","unstructured":"Richardson, D.R. (1999) The therapeutic potential of iron chelators. Expert Opin. Investig. Drugs, 8, 2141\u20132158.","journal-title":"Expert Opin. Investig. Drugs"},{"key":"8_CR53","unstructured":"Medical News Today (2005) FDA grants priority review for Exjade(R) for the treatment of chronic iron overload due to blood transfusions, http:\/\/www.medicalnewstoday.com\/medicalnews.php?newsid=26610 ."},{"key":"8_CR54","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1182\/blood-2006-02-002394","volume":"107","author":"E.J. Neufeld","year":"2006","unstructured":"Neufeld, E.J. (2006) Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: New data, new questions. Blood, 107, 3436\u20133441.","journal-title":"Blood"},{"key":"8_CR55","first-page":"873","volume":"91","author":"A. Piga","year":"2006","unstructured":"Piga, A., Galanello, R., Forni, G.L., Cappellini, M.D., Origa, R., Zappu, A., Donato, G., Bordone, E., Lavagetto, A., Zanaboni, L., Sechaud, R., Hewson, N., Ford, J.M., Opitz, H., and Alberti, D. (2006) Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica, 91, 873\u2013880.","journal-title":"Haematologica"},{"key":"8_CR56","first-page":"353","volume-title":"The Development of Iron Chelators for Clinical Use","author":"R.C. Hider","year":"1994","unstructured":"Hider, R.C., Porter, J.B., and Singh, S. (1994) The design of therapeutically useful iron chelators. In: The Development of Iron Chelators for Clinical Use (Bergeron, R.J. and Brittenham, G.M., Eds.), CRC, Boca Raton, pp. 353\u2013371."},{"key":"8_CR57","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1600-0773.1997.tb00390.x","volume":"80","author":"M. Gassen","year":"1997","unstructured":"Gassen, M. and Youdim, M.B. (1997) The potential role of iron chelators in the treatment of Parkinson\u2019s disease and related neurological disorders. Pharmacol. Toxicol. 80, 159\u2013166.","journal-title":"Pharmacol. Toxicol"},{"key":"8_CR58","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.neurobiolaging.2004.01.005","volume":"25","author":"J.Y. Lee","year":"2004","unstructured":"Lee, J.Y., Friedman, J.E., Angel, I., Kozak, A., and Koh, J.Y. (2004) The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Neurobiol. Aging, 25, 1315\u20131321.","journal-title":"Neurobiol. Aging"},{"key":"8_CR59","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood.V76.11.2389.2389","volume":"76","author":"J.B. Porter","year":"1990","unstructured":"Porter, J.B., Morgan, J., Hoyes, K.P., Burke, L.C., Huehns, E.R., and Hider, R.C. (1990) Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice. Blood, 76, 2389\u20132396.","journal-title":"Blood"},{"key":"8_CR60","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0169-409X(00)00122-8","volume":"47","author":"J. Kreuter","year":"2001","unstructured":"Kreuter, J. (2001) Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 47, 65\u201381.","journal-title":"Adv. Drug Deliv. Rev"},{"key":"8_CR61","first-page":"354","volume-title":"The Development of Iron Chelators for Clinical Use","author":"K.N. Raymond","year":"1994","unstructured":"Raymond, K.N. and Xu, J. (1994) Siderophore-based hydroxypyridonate sequestering agents. In: The Development of Iron Chelators for Clinical Use (Bergeron, R.J. and Brittenham, G.M., Eds.), CRC Press, Boca Raton, pp. 354\u2013371."},{"key":"8_CR62","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000203851","volume":"95","author":"R.C. Hider","year":"1996","unstructured":"Hider, R.C., Choudhury, R., Rai, B.L., Dehkordi, L.S., and Singh, S. (1996) Design of orally active iron chelators. Acta Haematol. 95, 6\u201312.","journal-title":"Acta Haematol"},{"key":"8_CR63","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S0020-1693(99)00126-7","volume":"291","author":"A.E. Martell","year":"1999","unstructured":"Martell, A.E., Motekaitis, R.J., Sun, Y., Ma, R., Welch, M.J., and Pajeau, T. (1999) New chelating-agents suitable for the treatment of iron overload. Inorg. Chim. Acta, 291, 238\u2013246.","journal-title":"Inorg. Chim. Acta"},{"key":"8_CR64","first-page":"237","volume":"36","author":"P. Caravan","year":"1997","unstructured":"Caravan, P. and Orvig, C. (1997) Tripodal aminophenolate ligand complexes of aluminum(III), gallium(III), and indium(III) in water. Inorg. Chem. 36, 237\u2013248.","journal-title":"Inorg. Chem"},{"key":"8_CR65","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1021\/jm990261n","volume":"43","author":"B. Faller","year":"2000","unstructured":"Faller, B., Spanka, C., Sergejew, T., and Tschinke, V. (2000) Improving the oral bioavailability of the iron chelator HBED by breaking the symmetry of the intramolecular H-bond network. J. Med. Chem. 43, 1467\u20131475.","journal-title":"J. Med. Chem"},{"key":"8_CR66","first-page":"237","volume-title":"The Development of Iron Chelators for Clinical Use","author":"R.J. Bergeron","year":"1994","unstructured":"Bergeron, R.J. and McManis, J.S. (1994) Synthesis and biological activity of hydroxamate-based iron chelators. In: The Development of Iron Chelators for Clinical Use (Bergeron, R.J. and Brittenham, G.M., Eds.), CRC, Boca Raton, pp. 237\u2013273."},{"key":"8_CR67","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S0022-2143(98)90180-9","volume":"131","author":"D.R. Richardson","year":"1998","unstructured":"Richardson, D.R. and Ponka, P. (1998) Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease. J. Lab. Clin. Med. 131, 306\u2013315.","journal-title":"J. Lab. Clin. Med"},{"key":"8_CR68","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0896-6273(01)00317-8","volume":"30","author":"R.A. Cherny","year":"2001","unstructured":"Cherny, R.A., Atwood, C.S., Xilinas, M.E., Gray, D.N., Jones, W.D., McLean, C.A., Barnham, K.J., Volitakis, I., Fraser, F.W., Kim, Y., Huang, X., Goldstein, L.E., Moir, R.D., Lim, J.T., Beyreuther, K., Zheng, H., Tanzi, R.E., Masters, C.L., and Bush, A.I. (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer\u2019s disease transgenic mice. Neuron, 30, 665\u2013676.","journal-title":"Neuron"},{"key":"8_CR69","doi-asserted-by":"publisher","first-page":"23223","DOI":"10.1074\/jbc.274.33.23223","volume":"274","author":"R.A. Cherny","year":"1999","unstructured":"Cherny, R.A., Legg, J.T., McLean, C.A., Fairlie, D.P., Huang, X., Atwood, C.S., Beyreuther, K., Tanzi, R.E., Masters, C.L., and Bush, A.I. (1999) Aqueous dissolution of Alzheimer\u2019s disease Abeta amyloid deposits by biometal depletion. J. Biol. Chem. 274, 23223\u201323228.","journal-title":"J. Biol. Chem"},{"key":"8_CR70","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1046\/j.1432-1327.2000.01452.x","volume":"267","author":"C. Loske","year":"2000","unstructured":"Loske, C., Gerdemann, A., Schepl, W., Wycislo, M., Schinzel, R., Palm, D., Riederer, P., and Munch, G. (2000) Transition metal-mediated glycoxidation accelerates cross-linking of beta-amyloid peptide. Eur. J. Biochem. 267, 4171\u20134178.","journal-title":"Eur. J. Biochem"},{"key":"8_CR71","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1001\/archneur.60.12.1685","volume":"60","author":"C.W. Ritchie","year":"2003","unstructured":"Ritchie, C.W., Bush, A.I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.X., Tammer, A., Carrington, D., Mavros, C., Volitakis, I., Xilinas, M., Ames, D., Davis, S., Beyreuther, K., Tanzi, R.E., and Masters, C.L. (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial. Arch. Neurol. 60, 1685\u20131691.","journal-title":"Arch. Neurol"},{"key":"8_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/14656566.7.1.1","volume":"7","author":"P.M. Doraiswamy","year":"2006","unstructured":"Doraiswamy, P.M. and Xiong, G.L. (2006) Pharmacological strategies for the prevention of Alzheimer\u2019s disease. Expert Opin. Pharmacother. 7, 1\u201310.","journal-title":"Expert Opin. Pharmacother"},{"key":"8_CR73","first-page":"117","volume-title":"Polymeric Site-Specific Pharmacotherapy","author":"H. Brem","year":"1994","unstructured":"Brem, H., Walter, K.A., Tamargo, R.J., Olivi, A., and Langer, R. (1994) Drug delivery to the brain. In: Polymeric Site-Specific Pharmacotherapy (Domb, A.J., Ed.), John Wiley & Sons, New York, pp. 117\u2013139."},{"key":"8_CR74","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/10611860290031877","volume":"10","author":"J. Kreuter","year":"2002","unstructured":"Kreuter, J., Shamenkov, D., Petrov, V., Ramge, P., Cychutek, K., Koch-Brandt, C., and Alyautdin, R. (2002) Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target. 10, 317\u2013325.","journal-title":"J. Drug Target"},{"key":"8_CR75","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1021\/js980084y","volume":"87","author":"U. Schroeder","year":"1998","unstructured":"Schroeder, U., Sommerfeld, P., Ulrich, S., and Sabel, B.A. (1998) Nanoparticle technology for delivery of drugs across the blood-brain barrier. J. Pharm. Sci. 87, 1305\u20131307.","journal-title":"J. Pharm. Sci"},{"key":"8_CR76","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3109\/02652049809006836","volume":"15","author":"R.N. Alyautdin","year":"1998","unstructured":"Alyautdin, R.N., Tezikov, E.B., Ramge, P., Kharkevich, D.A., Begley, D.J., and Kreuter, J. (1998) Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: An in situ brain perfusion study. J. Microencapsul. 15, 67\u201374.","journal-title":"J. Microencapsul"},{"key":"8_CR77","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ijdevneu.2005.11.012","volume":"24","author":"T. Siegemund","year":"2006","unstructured":"Siegemund, T., Paulke, B.R., Schmiedel, H., Bordag, N., Hoffmann, A., Harkany, T., Tanila, H., Kacza, J., and Hartig, W. (2006) Thioflavins released from nanoparticles target fibrillar amyloid beta in the hippocampus of APP\/PS1 transgenic mice. Int. J. Dev. Neurosci. 24, 195\u2013201.","journal-title":"Int. J. Dev. Neurosci"},{"key":"8_CR78","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ejpb.2004.07.009","volume":"59","author":"Z. Cui","year":"2005","unstructured":"Cui, Z., Lockman, P.R., Atwood, C.S., Hsu, C.H., Gupte, A., Allen, D.D., and Mumper, R.J. (2005) Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer\u2019s and other CNS diseases. Eur. J. Pharm. Biopharm. 59, 263\u2013272.","journal-title":"Eur. J. Pharm. Biopharm"},{"key":"8_CR79","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3233\/JAD-2005-7405","volume":"7","author":"T.B. Shea","year":"2005","unstructured":"Shea, T.B., Ortiz, D., Nicolosi, R.J., Kumar, R., and Watterson, A.C. (2005) Nanosphere-mediated delivery of vitamin E increases its efficacy against oxidative stress resulting from exposure to amyloid beta. J. Alzheimer\u2019s Dis. 7, 297\u2013301.","journal-title":"J. Alzheimer\u2019s Dis"},{"key":"8_CR80","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.neulet.2006.07.020","volume":"406","author":"G. Liu","year":"2006","unstructured":"Liu, G., Men, P., Harris, P.L., Rolston, R.K., Perry, G., and Smith, M.A. (2006) Nanoparticle iron chelators: A new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci. Lett. 406, 189\u2013193.","journal-title":"Neurosci. Lett"},{"key":"8_CR81","first-page":"234","volume":"3","author":"M.N. Ravi Kumar","year":"2000","unstructured":"Ravi Kumar, M.N. (2000) Nano and microparticles as controlled drug delivery devices. J. Pharm. Sci. 3, 234\u2013258.","journal-title":"J. Pharm. Sci"},{"key":"8_CR82","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1083\/jcb.138.4.877","volume":"138","author":"B. Dehouck","year":"1997","unstructured":"Dehouck, B., Fenart, L., Dehouck, M.P., Pierce, A., Torpier, G., and Cecchelli, R. (1997) A new function for the LDL receptor: Transcytosis of LDL across the blood-brain barrier. J. Cell Biol. 138, 877\u2013889.","journal-title":"J. Cell Biol"},{"key":"8_CR83","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00118-6","volume":"47","author":"R.H. Muller","year":"2001","unstructured":"Muller, R.H., Jacobs, C., and Kayser, O. (2001) Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47, 3\u201319.","journal-title":"Adv. Drug Deliv. Rev"},{"key":"8_CR84","volume-title":"Untersuchungen zur Ueberwindung der Blut-Hirn-Schranke mit Hilfe von Nanopartileln","year":"1998","unstructured":"Ramge, P. (Ed.) (1998) Untersuchungen zur Ueberwindung der Blut-Hirn-Schranke mit Hilfe von Nanopartileln, Shaker Verlag, Aachen."},{"key":"8_CR85","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0022-3565(24)35204-8","volume":"291","author":"L. Fenart","year":"1999","unstructured":"Fenart, L., Casanova, A., Dehouck, B., Duhem, C., Slupek, S., Cecchelli, R., and Betbeder, D. (1999) Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. J. Pharmacol. Exp. Ther. 291, 1017\u20131022.","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"8_CR86","volume-title":"Physiology of the CSF and Blood-Brain Barriers","year":"1996","unstructured":"Davson, H. and Segal, M.B. (Ed.) (1996) Physiology of the CSF and Blood-Brain Barriers, CRC Press, Boca Raton, FL."},{"key":"8_CR87","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood.V72.5.1497.1497","volume":"72","author":"J.B. Porter","year":"1988","unstructured":"Porter, J.B., Gyparaki, M., Burke, L.C., Huehns, E.R., Sarpong, P., Saez, V., and Hider, R.C. (1988) Iron mobilization from hepatocyte monolayer cultures by chelators: The importance of membrane permeability and the iron-binding constant. Blood, 72, 1497\u20131503.","journal-title":"Blood"},{"key":"8_CR88","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.bbadis.2005.06.006","volume":"1741","author":"G. Liu","year":"2005","unstructured":"Liu, G., Garrett, M.R., Men, P., Zhu, X., Perry, G., and Smith, M.A. (2005) Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochim. Biophys. Acta, 1741, 246\u2013252.","journal-title":"Biochim. Biophys. Acta"},{"key":"8_CR89","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1016\/S0960-894X(98)00569-1","volume":"8","author":"G. Liu","year":"1998","unstructured":"Liu, G., Bruenger, F.W., Miller, S.C., and Arif, A.M. (1998) Molecular structure and biological and pharmacological properties of 3-hydroxy-2-methyl-1-(beta-D-ribofuranosyl or pyranosyl)-4-pyridinone: Potential iron overload drugs for oral administration. Bioorg. Med. Chem. Lett. 8, 3077\u20133080.","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"8_CR90","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1081\/NCN-120030718","volume":"23","author":"G. Liu","year":"2004","unstructured":"Liu, G., Men, P., Kenner, G.H., Miller, S.C., and Bruenger, F.W. (2004) Acyclonucleoside iron chelators of 1-(2-hydroxyethoxy)methyl-2-alkyl-3-hydroxy-4-pyridinones: Potential oral iron chelation therapeutics. Nucleosides Nucleotides Nucleic Acids, 23, 599\u2013611.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"8_CR91","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1080\/00397919508015476","volume":"25","author":"G. Liu","year":"1995","unstructured":"Liu, G., Miller, S.C., and Bruenger, F.W. (1995) Synthesis of lipophilic 3-hydroxy-2-methyl-4-pyridinone derivatives. Syn. Commun. 25, 3247\u20133253.","journal-title":"Syn. Commun"},{"key":"8_CR92","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1002\/elps.11501401214","volume":"14","author":"T. Blunk","year":"1993","unstructured":"Blunk, T., Hochstrasser, D.F., Sanchez, J.C., Muller, B.W., and Muller, R.H. (1993) Colloidal carriers for intravenous drug targeting: Plasma protein adsorption patterns on surface-modified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis, 14, 1382\u20131387.","journal-title":"Electrophoresis"},{"key":"8_CR93","doi-asserted-by":"publisher","first-page":"9866","DOI":"10.1073\/pnas.94.18.9866","volume":"94","author":"M.A. Smith","year":"1997","unstructured":"Smith, M.A., Harris, P.L., Sayre, L.M., and Perry, G. (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA, 94, 9866\u20139868.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"8_CR94","unstructured":"Bangs Laboratories, Inc. (1999) TechNote 201, Working with microspheres."},{"key":"8_CR95","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1021\/jm00069a002","volume":"36","author":"P.S. Dobbin","year":"1993","unstructured":"Dobbin, P.S., Hider, R.C., Hall, A.D., Taylor, P.D., Sarpong, P., Porter, J.B., Xiao, G., and van der Helm, D. (1993) Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: Orally active iron chelators with clinical potential. J. Med. Chem. 36, 2448\u20132458.","journal-title":"J. Med. Chem"},{"key":"8_CR96","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1080\/00397919608004584","volume":"26","author":"G. Liu","year":"1996","unstructured":"Liu, G., Miller, S.C., and Bruenger, F.W. (1996) Efficient synthesis of N-[2-hydroxyethoxy)methyl]-2-alkyl-3-hydroxy-4-pyridinone by a modified Hilbert-Johnson reaction. Syn. Commun. 26, 2681\u20132686.","journal-title":"Syn. Commun"},{"key":"8_CR97","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1139\/v82-081","volume":"60","author":"M.J. Robins","year":"1982","unstructured":"Robins, M.J. and Hatfield, P.W. (1982) Nucleic acid related compounds. 37. Convenient and high-yield synthesis of N-[(2-hydroxyethoxy)methyl] heterocycles as \u201cacyclic nucleoside\u201d analogues. Can. J. Chem. 60, 547\u2013553.","journal-title":"Can. J. Chem"},{"key":"8_CR98","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1021\/jm00286a024","volume":"14","author":"H.J. Schaeffer","year":"1971","unstructured":"Schaeffer, H.J., Gurwara, S., Vince, R., and Bittner, S. (1971) Novel substrate of adenosine deaminase. J. Med. Chem. 14, 367\u2013369.","journal-title":"J. Med. Chem"},{"key":"8_CR99","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1021\/jm00168a033","volume":"33","author":"M. Streater","year":"1990","unstructured":"Streater, M., Taylor, P.D., Hider, R.C., and Porter, J. (1990) Novel 3-hydroxy-2(1H)-pyridinones. Synthesis, iron(III)-chelating properties, and biological activity. J. Med. Chem. 33, 1749\u20131755.","journal-title":"J. Med. Chem"},{"key":"8_CR100","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1021\/ic00279a022","volume":"27","author":"W.O. Nelson","year":"1988","unstructured":"Nelson, W.O., Timothy, B., Karpishin, T.B., Retting, S.J., and Orvig, C. (1988) Aluminum and gallium compounds of 3-hydroxy-4-pyridinones: Synthesis, characterization, and crystallography of biologically active complexes with unusual hydrogen bonding. Inorg. Chem. 27, 1045\u20131051.","journal-title":"Inorg. Chem"},{"key":"8_CR101","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1071\/CH9761329","volume":"29","author":"R.L.N. Harris","year":"1976","unstructured":"Harris, R.L.N. (1976) Potential wool growth inhibitors. Improved synthesis of mimosine and related 4(1H)-pyridones. Australian J. Chem. 29, 1329\u20131334.","journal-title":"Australian J. Chem"},{"key":"8_CR102","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1046\/j.1471-4159.2000.0740270.x","volume":"74","author":"L.M. Sayre","year":"2000","unstructured":"Sayre, L.M., Perry, G., Harris, P.L., Liu, Y., Schubert, K.A., and Smith, M.A. (2000) In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer\u2019s disease: A central role for bound transition metals. J. Neurochem. 74, 270\u2013279.","journal-title":"J. Neurochem"},{"key":"8_CR103","volume-title":"Nanomaterials for Medical Diagnosis and Therapy","author":"G. Liu","year":"2007","unstructured":"Liu, G., Men, P., Perry, G., and Smith, M.A. (2007) Nanoparticles for the treatment of Alzheimer\u2019s disease: Theoretical rationale, present status and future perspectives. In: Nanomaterials for Medical Diagnosis and Therapy (Kumar, C.S.S.R., Ed.), Wiley-VCH Verlag GmbH & Co. KGaA. (Nanotechnologies for the Life Sciences) Weinheim, pp. 644\u2013706."},{"key":"8_CR104","volume-title":"Chemistry of Protein Conjugation and Cross-Linking","year":"1991","unstructured":"Wong, S.S. (Ed.) (1991) Chemistry of Protein Conjugation and Cross-Linking, CRC Press, Boca Raton, Fl."},{"key":"8_CR105","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1021\/bc00008a001","volume":"2","author":"Y. Arano","year":"1991","unstructured":"Arano, Y., Matsushima, H., Tagawa, M., Koizumi, M., Endo, K., Konishi, J., and Yokoyama, A. (1991) A novel bifunctional metabolizable linker for the conjugation of antibodies with radionuclides. Bioconjug. Chem. 2, 71\u201376.","journal-title":"Bioconjug. Chem"},{"key":"8_CR106","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1399-3011.1987.tb03319.x","volume":"30","author":"P.S. Anjaneyulu","year":"1987","unstructured":"Anjaneyulu, P.S. and Staros, J.V. (1987) Reactions of N-hydroxysulfosuccinimide active esters. Int. J. Pept. Protein Res. 30, 117\u2013124.","journal-title":"Int. J. Pept. Protein Res"},{"key":"8_CR107","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/0003-2697(86)90176-4","volume":"156","author":"J.V. Staros","year":"1986","unstructured":"Staros, J.V., Wright, R.W., and Swingle, D.M. (1986) Enhancement by N-hydroxysulfosuccinimide of water-soluble carbodiimide-mediated coupling reactions. Anal. Biochem. 156, 220\u2013222.","journal-title":"Anal. Biochem"},{"key":"8_CR108","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1166\/jnn.2003.077","volume":"4","author":"J. Kreuter","year":"2004","unstructured":"Kreuter, J. (2004) Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J. Nanosci. Nanotechnol. 4, 484\u2013488.","journal-title":"J. Nanosci. Nanotechnol"}],"container-title":["Methods in Molecular Biology","Free Radicals and Antioxidant Protocols"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-60327-029-8_8.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T15:24:08Z","timestamp":1739460248000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-60327-029-8_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,25]]},"ISBN":["9781588297105","9781603270298"],"references-count":108,"URL":"https:\/\/doi.org\/10.1007\/978-1-60327-029-8_8","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-1-60327-029-8","asserted-by":"object"}]},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,25]]}}}